Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) binding site , is demonstrating promising outcomes in initial patient trials . Recent https://socialmarkz.com/story11993759/retatrutide-emerging-research-and-possible-medical-roles